Omalizumab is an effective treatment for patients with chronic spontaneous urticaria (CSU).
In routine clinical practice, physicians often face complex cases of CSU and need to decide …

Background In chronic spontaneous urticaria (CSU), the guidelines recommend very limited
diagnostic procedures during the routine workup, although additional investigations might …

Objectives Inflammatory rheumatic and musculoskeletal diseases (iRMDs) are associated
with increased systemic bone loss that is mediated by chronic inflammation, treatment with …

To the Editor, GA2LEN, the Global Allergy and Asthma European Network, and HAE international
(HAEi), the global umbrella organization for the world's hereditary angioedema (HAE) …

Objective To describe the perception of the current role of systemic glucocorticoids in the
management of rheumatoid arthritis (RA) by examining their importance and the current level of …

Background Idiopathic mast cell activation syndrome (MCAS) is characterized by three
diagnostic criteria: (1) episodic mast cell (MC)‐driven signs/symptoms of at least two organ …

Background Lanadelumab has been available in Germany for the prophylactic treatment of
hereditary angioedema since February 2019. Objective To investigate real-life treatment …

Background older people remain underrepresented in clinical trials, and evidence generated
in younger populations cannot always be generalized to older patients. Objective to …

Objective To evaluate sialic acid binding Ig-like lectin 1 (SIGLEC1) expression on monocytes
by flow cytometry as a type I interferon biomarker in idiopathic inflammatory myopathies (IIM…

Background The Angioedema Control Test (AECT) is a patient‐reported outcome measure
developed and validated for the assessment of disease control in patients with recurrent …